modelJ01DD64
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | CefpodoximeAndBetaLactamaseInhibitor | |
| ATC code: | J01DD64 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 15 | L |
| clearance: | 5.4 | L/h |
| other parameters in model implementation | ||
Cefpodoxime is a third-generation oral cephalosporin antibiotic, often co-formulated with a beta-lactamase inhibitor to extend its spectrum against beta-lactamase-producing bacteria. This combination is used for treating infections such as respiratory tract infections, urinary tract infections, and skin infections caused by susceptible organisms. The ATC code J01DD64 refers specifically to cefpodoxime combined with a beta-lactamase inhibitor (such as clavulanic acid or tazobactam), which is not approved or widely available in all regions.
Pharmacokinetics
Pharmacokinetic parameter estimates for adult healthy volunteers based on literature of cefpodoxime proxetil administered orally with a beta-lactamase inhibitor, extrapolated predominantly from studies on cefpodoxime alone. No direct published PK studies specific to the fixed combination are available.
References
Kays, MB, et al., & Miles, DO (1999). In vitro activity and pharmacodynamics of oral beta-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri. Pharmacotherapy 19(11) 1308–1314. DOI:10.1592/phco.19.16.1308.30869 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10555936
Birgy, A, et al., & Bonacorsi, S (2021). Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections. The Journal of antimicrobial chemotherapy 76(11) 2839–2846. DOI:10.1093/jac/dkab289 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34453533
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)